DOCSLIB.ORG

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients with Type 2 Diabetes a 1-Year, Randomized, Treat-To-Target Trial (BEGIN Once Long)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients with Type 2 Diabetes a 1-Year, Randomized, Treat-To-Target Trial (BEGIN Once Long) Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes A 1-year, randomized, treat-to-target trial (BEGIN Once Long) 1 6 BERNARD ZINMAN, MD LARS ENDAHL, PHD as a result of b-cell failure. Approximately 2 7 ATHENA PHILIS-TSIMIKAS, MD CHANTAL MATHIEU, MD 3 50% of patients with type 2 diabetes may BERTRAND CARIOU, MD, PHD ON BEHALF OF THE NN1250-3579 4 require insulin therapy in addition to oral YEHUDA HANDELSMAN, MD (BEGIN ONCE LONG)TRIAL 5 antidiabetic drugs (OADs) within 6 years HELENA W. RODBARD, MD INVESTIGATORS* 6 of diabetes diagnosis (2,3). Clinical guide- THUE JOHANSEN, MD lines by the American Diabetes Associa- tion and European Association for the OBJECTIVEdTo compare ultra–long acting insulin degludec with glargine for efficacy and Study of Diabetes currently recommend safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic initiating basal insulin in patients with drugs (OADs). type 2 diabetes either directly after met- formin or after maximizing a combination RESEARCH DESIGN AND METHODSdIn this 1-year, parallel-group, randomized, of OADs with or without glucagonlike 2 open-label, treat-to-target trial, adults with type 2 diabetes with A1C of 7 10% taking OADs peptide-1 receptor agonists and then ti- were randomized 3:1 to receive once daily degludec or glargine, both with metformin. Insulin trating insulin to meet a glycosylated he- was titrated to achieve prebreakfast plasma glucose (PG) of 3.924.9 mmol/L. The primary end fi moglobin (A1C) target of 7% without point was con rmation of noninferiority of degludec to glargine in A1C reduction after 52 weeks fi in an intent-to-treat analysis. signi cant hypoglycemia (4,5). Several barriers to introducing insulin RESULTSdIn all, 1,030 participants (mean age 59 years; baseline A1C 8.2%) were random- have been identified that may result in ized (degludec 773, glargine 257). Reduction in A1C with degludec was similar (noninferior) to delayed achievement of glycemic control that with glargine (1.06 vs. 1.19%), with an estimated treatment difference of degludec to and progression of diabetes complica- glargine of 0.09% (95% CI 20.04 to 0.22). Overall rates of confirmed hypoglycemia (PG ’ , tions (6,7). These barriers include patients 3.1 mmol/L or severe episodes requiring assistance) were similar, with degludec and glargine fear of injections and misconceptions at 1.52 versus 1.85 episodes/patient-year of exposure (PYE). There were few episodes of noc- ’ turnal confirmed hypoglycemia in the overall population, and these occurred at a lower rate with about insulin therapy, clinicians fear of degludec versus glargine (0.25 vs. 0.39 episodes/PYE; P = 0.038). Similar percentages of patients perceived complexity of insulin regimens, in both groups achieved A1C levels ,7% without hypoglycemia. End-of-trial mean daily insulin andbothparties’ fear that introducing doses were 0.59 and 0.60 units/kg for degludec and glargine, respectively. Adverse event rates insulin will negatively affect patient life- were similar. style and weight gain (8). Additionally, d the risk, consequences, and fear of hy- CONCLUSION Insulins degludec and glargine administered once daily in combination poglycemia remain a significant limiting with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with degludec. factor in intensifying insulin therapy and optimizing glycemic control (9). Long-acting insulin analogs have beendevelopedtoproduceamorephys- iological basal insulin action than seen he increasing prevalence of type 2 The landmark U.K. Prospective Diabetes fi with such human insulin preparations as Tdiabetes and its associated com- Study demonstrated the bene ts of im- neutral protamine Hagedorn (NPH) in- fi plications pose a signi cant global proved glucose control and highlighted sulin, and they are associated with lower health care and economic burden (1). the progressive nature of type 2 diabetes hypoglycemia rates (particularly noctur- ccccccccccccccccccccccccccccccccccccccccccccccccc nal) while achieving similar glycemic 1 control (10–12). These analogs have low- From the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; the 2Scripps Whittier Diabetes Institute, La Jolla, California; the 3Clinique d’Endocrinologie, ered the barrier for insulin introduction in l’Institut du Thorax, CHU Nantes, Nantes, France; the 4Metabolic Institute of America, Tarzana, California; patients with type 2 diabetes and are rec- 5Endocrine and Metabolic Consultants, Rockville, Maryland; 6Novo Nordisk A/S, Søborg, Denmark; and 7 ommended when OADs alone cannot UZ Leuven, University of Leuven, Leuven, Belgium. maintain glucose control (10,12,13). Corresponding author: Chantal Mathieu, [email protected]. Received 21 June 2012 and accepted 28 August 2012. There is still a need, however, for the devel- DOI: 10.2337/dc12-1205. Clinical trial reg. no. NCT00765817, clinicaltrials.gov. opment of basal insulins with improved This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 pharmacokinetics and pharmacodynamics, .2337/dc12-1205/-/DC1. with the goal of achieving glycemic targets *A complete listing of trial investigators are listed in the Supplementary Data online. © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly in more patients with even less hypogly- cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ cemic risk (14). Insulin degludec is a licenses/by-nc-nd/3.0/ for details. novel, ultra–long acting basal insulin. On care.diabetesjournals.org DIABETES CARE 1 Diabetes Care Publish Ahead of Print, published online October 5, 2012 Initiating insulin degludec in type 2 diabetes subcutaneous injection, degludec forms a frequency of OADs (metformin mono- measured blood glucose with a glucose depot of soluble multihexamers that dis- therapy or metformin in any combination meter (Abbott Diabetes Care, Abbot Park, sociates slowly and consistently, resulting with insulin secretagogues [sulfonyl- IL), with test strips calibrated to plasma in a flat, stable profile and a duration of urea or glinide, DPP-4 inhibitor] or a- values to obtain PG readings. The frequent action longer than 42 h (15,16). A previ- glucosidase-inhibitor) for $3months visit schedule for first 26 weeks and treat- ous phase 2 clinical trial comparing once before screening. Participants were ex- to-target approach were chosen to ensure daily degludec with glargine in insulin- cluded if they received thiazolidinediones, optimal titration. naive patients with type 2 diabetes (17) and exenatide or liraglutide within 3 months The primary end point was change in two phase 3 studies comparing once daily of screening or if they had clinically signi- A1C from baseline after 52 weeks. Other degludec with glargine in basal-bolus ficant cardiovascular, hepatic, renal or efficacy assessments included change therapy in patients with type 1 (18) and oncologic disease; recurrent severe hypo- from baseline in central laboratory– type 2 diabetes (19) demonstrated that glycemia; hypoglycemia unawareness; or measured fasting PG (FPG), SMBG, A1C degludec provides similar glycemic con- proliferative retinopathy. ,7% responders, and functional health trol with less hypoglycemia than glargine. Eligible participants were random- status (assessed by the 36-item short- BEGIN Once Long is the largest phase ized 3:1 to receive once daily degludec form health survey version 2.0 [SF-36]). 3 study in the clinical development pro- (100 U/mL, 3 mL PDS290; Novo Nor- Safety assessments included adverse gram of insulin degludec and was de- disk, Bagsværd, Denmark) or glargine events (AEs), hypoglycemic episodes, in- signed as a 52-week, treat-to-target trial to (Lantus, 100 U/mL, 3 mL SoloStar; sanofi- sulin dose, body weight, injection site compare the efficacy and safety of insulin aventis, Paris, France) by means of a cen- reactions, abnormal findings related degludec with those of insulin glargine, tralized, computer–generated, interactive to physical examination, vital signs, both administered in a basal regimen in voice and web response system that gener- fundoscopy, electrocardiogram (ECG), combination with metformin, in insulin- ated randomization blocks. Randomization and laboratory tests (including insulin naive participants with type 2 diabetes (3:1) ensured adequate exposure to de- antibodies). Confirmed hypoglycemic ep- inadequately controlled with OADs. gludec in accordance with regulatory guide- isodes included either episodes con- lines (22). Investigators and participants firmed by SMBG corresponding to PG RESEARCH DESIGN AND were not blinded to treatment. Treatment value ,3.1mmol/Lorsevereepisodes METHODSdThis 52-week, random- group assignment was blinded for individ- requiring assistance (no SMBG confirma- ized, controlled, parallel-group, open- uals involved as titration surveillance mon- tion) (4). Hypoglycemic episodes occur- label, multinational, treat-to-target, itors, internal safety committee members, ring from 0001 to 0559 h (inclusive) were noninferiority trial compared the efficacy external committee members responsible classified as nocturnal. Treatment-emergent and safety of once daily insulin degludec for cardiovascular
Load more

Recommended publications
  • Does Addition of Vildagliptin to Metformin Monotherapy Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus?
    PRACTICE pOINT www.nature.com/clinicalpractice/endmet Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus? Original article Bosi E et al. (2007) Effects of vildagliptin on OUTCOME MEASURES glucose control over 24 weeks in patients with type 2 diabetes The primary outcome measure was the change inadequately controlled with metformin. Diabetes Care 30: 890–895 in HbA1c level from baseline to study end. Secondary outcome measures included FPG SYNOPSIS levels, lipid profiles, β-cell function, and the KEYWORDS dipeptidyl peptidase 4 inhibitor, incidence and severity of adverse events. glycemic control, HbA1c, type 2 diabetes mellitus, vildagliptin RESULTS BACKGROUND The 50 mg vildagliptin, 100 mg vildagliptin Metformin is frequently prescribed as the and placebo groups comprised 177, 185, and first-line treatment for type 2 diabetes mellitus 182 patients, respectively. Participants were (T2DM); however, additional antidiabetic agents predominantly white and obese, with a mean might be required when glycemic control is age of 54 years. The mean duration of T2DM poor. was 6.2 years, the mean duration of metformin monotherapy was 17 months, and the mean OBJECTIVE metformin dose was 2,100 mg daily. The study To assess the efficacy and safety of the dipeptidyl was completed by >83% of patients in each peptidase 4 (DPP4) inhibitor vildagliptin as group. The mean baseline HbA1c level was 8.4% an add-on to metformin monotherapy. and the mean baseline FPG level was 9.9 mmol/l. Treatment with vildagliptin improved both of DESIGN AND INTERVENTION these parameters. The between-treatment This was a 24-week, multicenter, double- difference (vildagliptin minus placebo) in HbA1c blind, placebo-controlled, randomized study at study end was –0.7% and –1.1% with 50 mg of patients with T2DM inadequately controlled and 100 mg vildagliptin, respectively (P <0.001 with metformin monotherapy.
    [Show full text]
  • Galvus Data Sheet
    1 NEW ZEALAND DATA SHEET 1 GALVUS (50 mg tablets) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Vildagliptin: 1-[(3-Hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile. One tablet of Galvus® contains 50 mg of vildagliptin. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Galvus 50 mg: white to light yellowish, round (8 mm diameter) flat faced with beveled edges, unscored tablet. One side is debossed with "NVR", and the other side with "FB". 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Galvus is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. • as monotherapy. • in dual combination with metformin, a sulphonylurea (SU), or a thiazolidinedione (TZD) when diet, exercise and a single antidiabetic agent do not result in adequate glycaemic control. • In triple combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. • In combination with insulin (with or without metformin) when diet, exercise and a stable dose of insulin do not result in adequate glycaemic control. 4.2 Dosage and method of administration Dose The management of antidiabetic therapy should be individualized. The recommended dose of Galvus is 50 mg once or twice daily. The maximum daily dose of Galvus is 100 mg. For monotherapy, and for combination with metformin, with a TZD or with insulin (with or without metformin), the recommended dose of Galvus is 50 mg or 100 mg daily. When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily.
    [Show full text]
  • Vildagliptin/Metformin Hydrochloride Novartis, INN-Vildagliptin/Metformin
    European Medicines Agency Evaluation of Medicines for Human Use Doc.Ref.: EMEA/CHMP/656453/2008 ASSESSMENT REPORT FOR Vildagliptin/metformin hydrochloride Novartis International Nonproprietary Name: vildagliptin / metformin hydrochloride Procedure No. EMEA/H/C/001050 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1 Submission of the dossier ........................................................................................................ 3 1.2 Steps taken for the assessment of the product.......................................................................... 3 2. SCIENTIFIC DISCUSSION................................................................................................. 4 2.1 Introduction.............................................................................................................................. 4 2.2 Quality aspects......................................................................................................................... 4 2.3 Non-clinical aspects................................................................................................................. 4 2.4 Clinical
    [Show full text]
  • Dipeptidyl Peptidase-4 Inhibitor Switching
    abetes & Di M f e t o a Tanaka et al., J Diabetes Metab 2016, 7:9 l b a o n l r i DOI: 10.4172/2155-6156.1000701 s u m o J Journal of Diabetes & Metabolism ISSN: 2155-6156 Research Article Open Access Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients Masami Tanaka*, Takeshi Nishimura, Risa Sekioka and Hiroshi Itoh Department of Internal Medicine, School of Medicine, Keio University 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan Abstract Objective: This retrospective cohort study aimed to investigate the significance of dipeptidyl peptidase-4 (DPP- 4) inhibitor switch therapy, which is currently not recommended by major diabetes guidelines. Methods: The subjects were 238 outpatients with type 2 diabetes who had been prescribed sitagliptin 50 mg daily, which was subsequently changed in one of three ways. Patients whose sitagliptin was switched to vildagliptin 50 mg twice daily were defined as the switched group. Patients whose sitagliptin was increased to 100 mg once daily were defined as the increased group. Patients who received an additional alfa-glucosidase inhibitor (α-GI) three times daily prior to meals and sitagliptin 50 mg once daily were defined as the added group. The primary endpoint was the glycated hemoglobin (HbA1c) value at 6 months after the medication change. Patients whose oral hypoglycemic agents were changed within 6 months after switching to vildagliptin, increasing sitagliptin, or adding α-GI were excluded from the full analysis set and the remaining patients were included in the per protocol analysis.
    [Show full text]
  • Eucreas, INN-Vildagliptin / Metformin Hydrochloride
    SCIENTIFIC DISCUSSION 1. Introduction The pathophysiology of Type 2 diabetes mellitus (T2DM) is characterised by deficient insulin activity arising from decreased insulin secretion secondary to beta cell failure, and/or compromised insulin action in peripheral target tissues (insulin resistance). This abnormal metabolic state is exacerbated by excess hepatic glucose production and altered metabolism of proteins and lipids, which along with hyperglycaemia, contribute to microvascular and macrovascular complications. T2DM accounts for approximately 85% to 95% of diabetes cases in developed regions like the European Union. Age and weight are established risk factors for T2DM. The majority of patients with T2DM are overweight or obese. Diet modification and exercise is the first line of treatment for T2DM. Pharmacologic intervention with one oral antidiabetic drug (OAD) is usually the next step in treatment. After 3 to 9 years of OAD monotherapy, patients typically require an additional intervention. The recommended first line treatment is metformin, which restrains hepatic glucose production and decreases peripheral insulin resistance. Sulphonylureas, which are insulin secretagogues, may be used as an alternative to patients intolerant to metformin, or as an addition to metformin. Other second line oral treatment alternatives include alpha-glucosidase inhibitors, meglitinides and thiazolidinediones. Recently the first GLP-1 analogue, exenatide, and the first DPP-4 inhibitors, sitagliptin and vildagliptin, were approved by the CHMP. Vildagliptin belongs to a new class of oral anti-diabetic drugs and is a selective and reversible inhibitor of Dipeptidyl peptidase 4 (DPP-4), the enzyme which inactivates the incretin hormones, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), hormones which significantly contribute to the maintenance of glucose homeostasis.
    [Show full text]
  • Combination Use of Insulin and Incretins in Type 2 Diabetes
    Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé CADTH Optimal Use Report Volume 3, Issue 1C Combination Use of Insulin and July 2013 Incretins in Type 2 Diabetes Supporting Informed Decisions This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). The report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time of report preparation. The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up to date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.
    [Show full text]
  • Essential Medicines List (EML) 2017 Application for the Revision Of
    Essential Medicines List (EML) 2017 Application for the revision of second line treatments of type II diabetes: considered agents that can be used in combination with metformin are sulfonylureas, meglitinides, alpha-glucosidase inhibitors, TZDs, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonists, basal insulins, bolus insulins, and biphasic insulins. General items 1. Summary statement of the proposal for inclusion, change or deletion In type 2 diabetes, when initial therapy with lifestyle interventions and metformin monotherapy are unsuccessful, a second oral or injectable agent is recommended. This is referred to as ‘second-line therapy’. Historically, insulin or sulfonylureas have been preferred second-line agents because of efficacy, side-effect profiles, long-term safety, and relative cost. Both insulin and sulfonylurea are listed as essential medicines, along with metformin. In 2013 the Expert Committee of Essential Medicines Selection and Use evaluated evidence comparing four groups of oral hypoglycemics: (1) dipeptidyl peptidase-4 (DPP-4) inhibitors, (2) thiazolidinediones, (3) alpha-glucosidase inhibitors, such as acarbose, and (4) meglitinides, against metformin (biguanide) and sulfonylureas (WHO Technical Report Series 985). The results from the 2013 review indicated that there were no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective treatment option. Based on these analyses, the Expert Committee recommended that “there was insufficient evidence to show that any of the medicines in the four groups (DPP-4 inhibitors, alphaglucosidase inhibitors, meglitinides, or thiazolidinediones) offered any efficacy or safety advantages over the existing medicines included in the EML”, (i.e. metformin first line and sulfonylurea second line). Since then, a new drug class has entered the market of several countries for the treatment of patients with T2D — sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
    [Show full text]
  • Vildagliptin/Metformin Hydrochloride) Film-Coated Tablet
    AUSTRALIAN PRODUCT INFORMATION – GALVUMET® (VILDAGLIPTIN/METFORMIN HYDROCHLORIDE) FILM-COATED TABLET 1 NAME OF THE MEDICINE vildagliptin/metformin hydrochloride 2 QUALITATIVE AND QUANTITATIVE COMPOSITION GALVUMET film coated tablets are available in 3 strengths: • GALVUMET 50/500: 50 mg vildagliptin and 500 mg metformin hydrochloride • GALVUMET 50/850: 50 mg vildagliptin and 850 mg metformin hydrochloride • GALVUMET 50/1000: 50 mg vildagliptin and 1,000 mg metformin hydrochloride For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM GALVUMET 50/500: light yellow, ovaloid bevelled edge, film-coated tablet imprinted with "NVR" on one side and "LLO" on the other side. GALVUMET 50/850: yellow, ovaloid bevelled edge, film-coated tablet imprinted with "NVR" on one side and "SEH" on the other side. GALVUMET 50/1000: dark yellow, ovaloid bevelled edge, film-coated tablet imprinted with "NVR" on one side and "FLO" on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For patients with Type 2 diabetes mellitus (T2DM): GALVUMET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. Treatment should not be initiated with this fixed-dose combination. GALVUMET is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea. GALVUMET is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
    [Show full text]
  • Adverse Drug Effects Observed with Vildagliptin Versus Pioglitazone Or
    Bundhun et al. BMC Pharmacology and Toxicology (2017) 18:66 DOI 10.1186/s40360-017-0175-0 RESEARCH ARTICLE Open Access Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials Pravesh Kumar Bundhun1, Girish Janoo2, Abhishek Rishikesh Teeluck2 and Feng Huang3* Abstract Background: Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM). In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglitazone or rosiglitazone respectively. Methods: Online databases were searched for studies comparing vildagliptin with pioglitazone/rosiglitazone. Adverse drug events were considered as the clinical endpoints in this analysis. We calculated Odds Ratios (OR) with 95% Confidence Intervals (CIs) using the RevMan 5.3 software. All the authors had full access to the data which were used and approved the final version of the manuscript. Results: A total number of 2396 patients were analyzed (1486 and 910 patients were treated with vildagliptin and pioglitazone/rosiglitazone respectively). Vildagliptin and pioglitazone/rosiglitazone were both associated with similar overall adverse drug events (OR: 1.00, 95% CI: 0.81–1.24; P = 1.00). Headache (OR: 0.88, 95% CI: 0.60–1.27; P = 0.49) and upper respiratory tract infection (OR: 0.95, 95% CI: 0.71–1.27; P = 0.75) were similarly observed. However, dizziness was significantly lower with pioglitazone/rosiglitazone (OR: 0.63, 95% CI: 0.43–0.92; P = 0.02).
    [Show full text]
  • Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use
    F E A T U R E A R TICLE Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use John R. White, Jr., PA, PharmD decade and a half ago, the on insulin biosynthesis and its inhibition creation of molecules that circumvent or choice of an oral antihypergly- of glucagon release.2 reduce the rate degradation by DPP-IV Acemic agent for any particu- Because GLP-1 stimulates insulin while maintaining the agonist effects of lar patient was in some ways a debate secretion only under hyperglycemic GLP-1 has been pursued aggressively. of nuance. Sulfonylureas (SUs) were conditions, there is minimal risk of One GLP-1 analog (exenatide) is avail- the only class available, and provid- hypoglycemia, making this molecule and able in the United States, and another ers were left to sift though pharmacoki- its congeners likely candidates for use as (liraglutide) is in phase III trials. netic, small efficacy, and sometimes sig- antihyperglycemic agents. GLP-1 is also In addition to GLP-1 analogs, mol- nificant side effect differences among associated with increased satiety, possi- ecules that inhibit the activity of DPP-IV the various choices within this class. The bly because it reduces the rate of gastric and thereby prolong the activity of situation today demands a more robust emptying. People with type 2 diabetes endogenous GLP-1 are of great interest. evaluation of multiple categories of med- have reduced circulating levels of GLP-1 Because GLP-1 analogs are proteina- ications with different mechanisms of but retain their ability to respond to this cious in structure, they will most likely action.
    [Show full text]
  • Ertugliflozin/ Sitagliptin 5/50 Mg, 15/50 Mg, 5/100 Mg and 15/100 Mg
    AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Ertugliflozin/Sitagliptin Proprietary Product Name: Steglujan Sponsor: Merck Sharpe and Dohme (Australia) Pty Ltd. Date of first round report: 18 October 2017 Date of second round report: 18 January 2018 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au> . About the Extract from the Clinical Evaluation Report • This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. • The words (Information redacted), where they appear in this document, indicate that confidential information has been deleted. • For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi> .
    [Show full text]
  • Efficacy and Short-Term Side Effects of Sitagliptin, Vildagliptin and Saxagliptin in Chinese Diabetes: a Randomized Clinical Trial
    ID: 18-0523 8 4 X Zhou, L Ding et al. Efficacy and short-term side 8:4 318–325 effects of DPP4 inhibitors RESEARCH Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial Xiao-jun Zhou1,*, Lin Ding1,*, Jia-xin Liu1, Le-qun Su2, Jian-jun Dong3 and Lin Liao1 1Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China 2Department of Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China 3Division of Endocrinology, Department of Medicine, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, China Correspondence should be addressed to L Su or J Dong or L Liao: [email protected] or [email protected] or [email protected] *(X Zhou and L Ding contributed equally to this work) Abstract Aims: To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) Key Words inhibitors in Chinese adults with newly diagnosed diabetes. f dipeptidyl peptidase-4 Materials and methods: In a multicenter, randomized study, we enrolled adults who were inhibitors either treatment naive or off prior anti-hyperglycemic therapy for at least 3 months. f hemoglobin A1c Eligible patients had hemoglobin A1c (HbA1c) concentrations of 6.5–9.5%. Three hundred f Chinese patients had been randomly allocated to sitagliptin 100 mg, once daily; vildagliptin 50 mg, f diabetes twice daily and saxagliptin 5 mg, once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c at week 12. This study was completed and registered with ClinicalTrials.gov, number NCT 01703637.
    [Show full text]